Matinas BioPharma ( (MTNB) ) has issued an update.
On March 11, 2025, Matinas BioPharma announced the appointment of Keith Murphy and Edward Neugeboren to its Board of Directors, following the resignations of Natasha Giordano and Matthew Wikler due to other professional obligations. The new appointees bring extensive experience in the biotech and pharmaceutical industries, which is expected to enhance the company’s strategic direction and shareholder value. The appointments are part of Matinas BioPharma’s ongoing efforts to strengthen its leadership team as it continues to advance its innovative therapies.
More about Matinas BioPharma
Matinas BioPharma is a biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology. One of its potential products, MAT2203, is an oral broad-spectrum treatment for invasive fungal infections, designed to overcome the limitations of current treatments by offering targeted delivery and reduced toxicity.
YTD Price Performance: -7.80%
Average Trading Volume: 480,743
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $2.77M
For an in-depth examination of MTNB stock, go to TipRanks’ Stock Analysis page.